文献速递心律失常血脂与心血管预防

新诊断房颤患者对疾病的认知状况

Disease understanding in patients newly diagnosed with atrial fibrillation.
PubMed 文献 · Heart · 2017-08-08

基于美国56个中心ORBIT II注册研究的SATELLITE子研究,对1004例新发房颤患者在基线与6个月时进行Likert量表调查,评估其对疾病与治疗的理解程度。患者对节律控制、消融、抗凝和复律的理解信心均不理想,高理解比例从左心耳封堵的8.5%到节律治疗的71.3%;6个月时仅华法林和直接口服抗凝药的理解显著提高(p<0.05),除消融外高理解与治疗使用无关。

要点

  • 新发房颤患者诊断时对口服抗凝获益的理解仅约一半,6个月内有所改善。
  • 6个月时对房颤治疗的整体理解仍不理想,需持续患者教育。
  • 除消融外,对某种治疗的高理解并未带来该治疗6个月时使用的增加。

核心结论

  • 约半数新发房颤患者在诊断时理解口服抗凝药的获益,且理解在最初6个月内改善。
  • 但6个月时对房颤治疗的理解仍不理想,结果提示需要持续的患者教育。

研究设计与样本

  • SATELLITE为ORBIT II注册研究的子研究,纳入美国56个中心的新发房颤患者。
  • 基线调查1004例,6个月随访调查786例,使用Likert量表评估疾病理解。

主要发现

  • 基线时对节律控制、消融、抗凝和复律的理解信心不理想,高理解比例从左心耳封堵的8.5%到节律治疗的71.3%。
  • 在病史与人口学因素中,教育水平是报告高疾病理解的最强预测因素。
  • 786例有6个月数据的患者中,仅华法林和直接口服抗凝药的高理解比例显著增加(p<0.05)。
  • 除消融外,对某一治疗方案的高理解与6个月时该治疗的使用增加无关。

关键数值与推荐

  • 高理解比例范围:左心耳封堵8.5%至节律治疗71.3%。
  • 6个月高理解显著增加仅见于华法林和直接口服抗凝药(p<0.05)。

临床怎么用

  • 应在新诊断房颤患者中开展持续、个体化的患者教育,尤其针对抗凝治疗的理解。
  • 不能假定患者对治疗的高理解会转化为该治疗的实际使用。

局限性

  • 为注册研究子研究的调查数据,理解程度基于患者自报的Likert量表。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment receipt at 6 months among treatment-naïve patients. METHODS: We analysed survey data from SATELLITE (Survey of Patient Knowledge and Personal Priorities for Treatment), a substudy of patients with new-onset AF enrolled in the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) II registry across 56 US sites. Patients were surveyed at the baseline and 6-month follow-up clinic visits using Likert scales. RESULTS: Among 1004 baseline survey responses, patients' confidence in their understanding of rhythm control, ablation, anticoagulation and cardioversion was suboptimal, with 'high' understanding ranging from 8.5% for left atrial appendage closure to 71.3% for rhythm therapy. Of medical history and demographic factors, education level was the strongest predictor of reporting 'high' disease understanding. Among the 786 patients with 6-month survey data, significant increases in the proportion reporting high understanding were observed (p<0.05) only for warfarin and direct oral anticoagulants (DOACs). With the exception of ablation, high understanding for a given therapeutic option was not associated with increased use of that therapy at 6 months. CONCLUSIONS: About half of patients with new-onset AF understood the benefits of oral anticoagulant at the time of diagnosis and understanding improved over the first 6 months. However, understanding of AF treatment remains suboptimal at 6 months. Our results suggest a need for ongoing patient education. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov. Identifier: NCT01701817.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Kaufman BG, Kim S, Pieper K, et al. Disease understanding in patients newly diagnosed with atrial fibrillation. Heart. 2017. PMID: 28790169. doi:10.1136/heartjnl-2017-311800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。